Cooperative Agreement NU2GGH002463

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $504,703 to the University of Georgia Research Foundation (UGA Research Foundation) to optimize a PCR-based assay for detecting and quantifying Trypanosoma cruzi infection. The key objectives are to increase the sensitivity of PCR detection of T. cruzi DNA in blood samples through techniques such as DNA fragmentation...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $133,800 to the Fundacion Instituto De Investigaciones Biotecnologicas in Argentina. The funding supports research to fully understand protein trafficking through the contractile vacuole complex (CVC) in the parasite Trypanosoma cruzi, the causative agent of Chagas disease. The research aims to...

This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to develop and validate nanotherapies to address three key issues in the treatment of chronic Chagas disease. The $666,319 award to the University of Virginia supports research to: 1) Treat chronic Chagas cardiomyopathy without impacting parasitemia or parasite reservoirs, 2) Eliminate parasite reservoirs in adipose tissue, and 3) Improve drug delivery and efficacy of...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $160,500 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Baylor College of Medicine to develop and validate a highly sensitive serological assay for detecting all geographic variances of Trypanosoma cruzi infection, which causes Chagas disease. This 2-year project aims to address the limitations of current Chagas diagnostic tests and reduce the burden on the healthcare system...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, will support the development of a panel of antibodies to detect markers of Trypanosoma cruzi infection, the causative agent of Chagas disease. The $449,408 award to Duke University, with a performance period from Jul 1, 2025 to Jun 30, 2027, aims to generate antibodies that can effectively diagnose acute and chronic Chagas...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $123,280 project grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to Instituto De Biologia Molecular Y Celular De Rosario (IBR) in Argentina. The grant aims to investigate the adaptive immune response against Trypanosoma cruzi, the parasite that causes Chagas disease, with the goal of developing effective vaccine candidates. The research will focus on enhancing CD8+ T cell...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $133,746 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Fundacion Instituto De Investigaciones Biotecnologicas, a non-profit research institute in Buenos Aires, Argentina. The grant supports high-throughput analysis of antibody responses against defined epitopes to prioritize diagnostic and prognostic markers for Chagas disease, a parasitic infection endemic to the Americas. The...

This $438,500 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will support the development of new tools to facilitate drug discovery for proteasomes in parasitic diseases associated with poverty, including neglected tropical diseases (NTDs). The key objectives are to address two key bottlenecks in advancing parasite proteasome research: 1) the time-consuming and limited purification of native parasite 20S...

The University of Texas Medical Branch at Galveston (UTMB) received a $440,000 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), to examine the role of the long non-coding RNA (lncRNA) CHAST in regulating the host immune response to Trypanosoma cruzi (T. cruzi) infection, the causative agent of Chagas disease. The project aims to elucidate how T. cruzi deregulates CHAST...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a 5-year, $134,067 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Asociación Benefica Prisma (Prisma), a Peruvian non-profit organization. The grant funds research to evaluate the impact of mesophilic anaerobic biodigestion (MAD) systems on the survival, viability, and infectivity of Taenia solium eggs, which can lead to devastating central nervous system infections if ingested....